HEALTHSTORY 654· AUGUST 3, 2026

California Supreme Court rules Gilead Sciences has no legal duty to fast-track a safer HIV drug

Pharmaceutical companies do not owe patients a legal duty to speed up development of a safer drug simply because a less safe version is already on the market. That concept, called a "duty to innovate," was at the center of a case brought…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 653BlackRock launches two tokenized money market funds for stablecoin reserve managers NEXT STORY 655 →Amazon gets $600 million back on Trump-era tariffs and will share some of it with customers

Keep reading

More from the desk.

02HEALTH

Lilly breast cancer combination receives regulatory approval

The short version is that Eli Lilly and Company secured approval for a breast cancer treatment combination. In plain terms, a drug combination is a therapeutic strategy that pairs two distinct agents to treat a disease, often aiming to…

health2 MIN

14HEALTH

Radiopharma giants merge in $1.65 billion deal after FDA rejection

Two leading radiopharmaceutical companies are merging in a transaction valued at at least $1.65 billion. This move follows a surprise FDA rejection for one of the firms. In plain terms, radiopharmaceuticals are medicines that deliver…

health2 MIN

37HEALTH

Sanfilippo syndrome gets its first gene therapy approval after more than a decade of research

A rare childhood disease called Sanfilippo syndrome now has an approved gene therapy, the first one in the disease's history. Gene therapy, in plain terms, is a treatment that introduces corrected genetic material into a patient's cells to…

health1 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk